GlaxoSmithKline announced a $2.2 billion cash acquisition of RAPT Therapeutics at $58 per share, sending RAPT stock surging 64% in pre-market trading. The deal gives GSK rights to RAPT's anti-IgE antibody, a therapy targeting food allergies that GSK views as a potential breakthrough treatment.